The COL5A2 antibody targets the α2 chain of type V collagen, a fibrillar collagen encoded by the COL5A2 gene. Type V collagen is a minor component of the extracellular matrix (ECM) and primarily forms heterotypic fibrils with type I collagen, playing a critical role in regulating fibril diameter and organization during collagen assembly. COL5A2 is expressed in tissues rich in connective tissue, such as skin, tendons, and blood vessels, where it contributes to structural integrity and mechanical stability.
Antibodies against COL5A2 are utilized in research to study its expression patterns, distribution, and involvement in diseases. Mutations in COL5A2 are linked to Ehlers-Danlos syndrome (EDS), a connective tissue disorder characterized by skin hyperelasticity, joint hypermobility, and tissue fragility. Additionally, altered COL5A2 expression has been observed in cancers, fibrosis, and wound healing, suggesting roles in tumor progression and ECM remodeling.
These antibodies enable detection via techniques like immunohistochemistry, Western blotting, and immunofluorescence, aiding in the investigation of COL5A2's functional interactions and pathological mechanisms. Research using COL5A2 antibodies also explores its potential as a biomarker or therapeutic target in connective tissue disorders and cancer.